This showed that CDK9i efficiently suppressed the levels of Mcl-1 and cFLIP not only in therapy-sensitive but, importantly, also in therapy-resistant melanoma cells (Fig. 5b and Supplementary Fig. 6a-b). The gene discussed is CFLAR; the disease is melanoma.